🔴 GT Biopharma is trading 5.2% down today as Nasdaq Composite falls 1.31%

GT Biopharma is trading at $0.27, down 5.23%, amid broader market weakness.

• No fresh company-specific announcement was identified on August 18, 2026.
• The Nasdaq Composite is down 1.31%, suggesting broader risk-off sentiment is contributing.
• Its August 14 quarterly report showed approximately $5.1 million in cash and runway through Q4 2026, but did not directly explain this session’s move.